| Age (years) |
65.00±7.08 |
66.00±9.70 |
0.480 |
| Sex, n (%) |
|
|
– |
| Male |
4 (40.0) |
3 (50.0) |
| Female |
6 (60.0) |
3 (50.0) |
| Arterial hypertension, n (%) |
4 (40.0) |
2 (33.3) |
0.796 |
| Diabetes mellitus, n (%) |
6 (60.0) |
2 (33.3) |
0.317 |
| Dyslipidemia, n (%) |
5 (50.0) |
2 (33.3) |
0.529 |
| Jaundice, n (%) |
9 (90.0) |
3 (50.0) |
0.016 |
| Treatment: total pancreatectomy, n (%) |
5 (50.0) |
3 (50.0) |
0.464 |
| Cephalic duodenopancreatectomy |
4 (40.0) |
1 (16.7) |
| Subtotal pancreatectomy |
0 |
1 (16.7) |
| Distal pancreatectomy |
1 (10.0) |
1 (16.7) |
| Operative time (min), median [range] |
360 [300–420] |
282 [270–360] |
0.050 |
| Intraoperative transfusions, n |
0.50±0.72 |
0 |
0.068 |
| Hospital stay (days), median (range) |
11.0 (7.0–28.0) |
10.5 (4.0–69.0) |
0.875 |
| Pancreatic complications, n (%) |
|
|
0.492 |
| Delayed gastric emptying |
2 (20.0) |
1 (16.7) |
| Pancreatic fistula (B, C) |
– |
– |
| Hemorrhage |
– |
2 (33.3) |
| Other |
|
|
| Respiratory infection |
2 (20.0) |
– |
| Urinary infection |
1 (10.0) |
– |
| Clavien-Dindo, n (%) |
|
|
0.200 |
| I |
1 (10.0) |
– |
| II |
4 (40.0) |
2 (33.3) |
| IIIa |
– |
– |
| IIIb |
– |
1 (16.7) |
| IV |
– |
– |
| V |
– |
1 (16.7) |
| Mortality (<30 days) |
0 |
0 |
– |
| Differentiation, n (%) |
|
|
0.282 |
| Good |
– |
0 |
| Moderate |
– |
3 (50.0) |
| Poor |
5 (50.0) |
3 (50.0) |
| Neurologic invasion, n (%) |
7 (70.0) |
3 (50.0) |
0.439 |
| Vascular invasion, n (%) |
3 (30.0) |
– |
0.150 |
| Lymphatic invasion, n (%) |
2 (20.0) |
1 (16.7) |
0.900 |
| Follow-up time (months), median [range] |
13 [2–28] |
16 [2–22] |
0.703 |
| Locoregional recurrence, n (%) |
0 |
1 (16.7) |
0.197 |
| Distant recurrence, n (%) |
3 (30.0) |
2 (33.3) |
0.893 |
| Free disease survival (months), median [range] |
11 [2–22] |
15 [6–22] |
0.423 |
| Mortality (>30 days), n (%) |
1 (10.0) |
1 (16.7) |
0.705 |
